{"name":"ASST Gaetano Pini-CTO","slug":"asst-gaetano-pini-cto","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Levobupivacaine 0,5%","genericName":"Levobupivacaine 0,5%","slug":"levobupivacaine-0-5","indication":"Local and regional anesthesia for surgical procedures","status":"marketed"},{"name":"Levobupivacaine 0,125%","genericName":"Levobupivacaine 0,125%","slug":"levobupivacaine-0-125","indication":"Other","status":"marketed"},{"name":"Mepivacaine 1%","genericName":"Mepivacaine 1%","slug":"mepivacaine-1","indication":"Local and regional anesthesia for infiltration, nerve block, and epidural anesthesia","status":"marketed"}]}],"pipeline":[{"name":"Levobupivacaine 0,5%","genericName":"Levobupivacaine 0,5%","slug":"levobupivacaine-0-5","phase":"marketed","mechanism":"Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.","indications":["Local and regional anesthesia for surgical procedures","Infiltration anesthesia","Nerve blocks","Epidural anesthesia"],"catalyst":""},{"name":"Levobupivacaine 0,125%","genericName":"Levobupivacaine 0,125%","slug":"levobupivacaine-0-125","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mepivacaine 1%","genericName":"Mepivacaine 1%","slug":"mepivacaine-1","phase":"marketed","mechanism":"Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.","indications":["Local and regional anesthesia for infiltration, nerve block, and epidural anesthesia","Dental anesthesia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNeVNfSXBMMW1FZ2pnNlZUWExHUzgwcDFwODFxX3lyQ3Fqa3ExRGx1Y0szUmdpbWFWWm5KUFBNcUN5LUdpeHRGMEpQYm9OSllMR0dIRnR6UGhLZUl3YjJUYnQzcE9TZTd1TlRRc1hIVWctZzZqbGRNUXl2cjh5aTdyVlFWVUNvVW5maDdiQVBLME9sMW4xdUQ0RWh6eHdVY2F2LVJEMDJUbzZkcUJoTWJvYm8tN2F6Z2NxM2FBRDJYUkZOYXM1cFBxN1prRy05dXNWV0MxOFZlUWNjbGJsU0tBcDYwNDBwM1g3TS1xRWI0MGY1X3pLMklORFd6b0stNDJtaUhOWDJvLURibzdrZm5V?oc=5","date":"2025-07-24","type":"trial","source":"European Medical Journal","summary":"Long-Term Effect of Selexipag in Systemic Sclerosis-Associated Digital Ulcers: A Case Control, Multicentre, Observational Study - European Medical Journal","headline":"Long-Term Effect of Selexipag in Systemic Sclerosis-Associated Digital Ulcers: A Case Control, Multicentre, Observationa","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}